Bone health in patients with brain tumors

Surgical Neurology

Volumn 68, Issue 5, 2007, Pages 525-533

  Da Silva, Arnaldo Neves ^a   Heras Herzig, Ailleen ^a   Schiff, David ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Anticoagulants; Antiepileptic drugs; Biphosphonates; Brain tumors; Calcium; Glucocorticoids; Osteoporosis; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBAMAZEPINE; CARMUSTINE; ETIRACETAM; GLUCOCORTICOID; HEPARIN; LAMOTRIGINE; LOMUSTINE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TEMOZOLOMIDE; TIAGABINE; TOPIRAMATE; VITAMIN D; VITAMIN K GROUP; WARFARIN; ZONISAMIDE;

ARTICLE; BLEEDING; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE NECROSIS; BRAIN TUMOR; CALCIUM INTAKE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; FRACTURE; HEMIPLEGIA; HUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RISK ASSESSMENT; SEIZURE; SUNLIGHT; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

ANTICOAGULANTS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; BRAIN NEOPLASMS; GLUCOCORTICOIDS; HUMANS;

EID: 35348996536     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surneu.2006.11.065     Document Type: Article

References (111)

1. Adinoff A.D., and Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309 (1983) 265-268
2. Andress D.L., Ozuna J., Tirschwell D., et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 59 (2002) 781-786
3. Atkinson S.A., Fraher L., Gundberg C.M., et al. Mineral homeostasis and bone mass in children treated for acute lymphoblastic leukemia. J Pediatr 114 (1989) 793-800
4. Barbour L.A., Kick S.D., Steiner J.F., et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170 (1994) 862-869
5. Barnes C., Newall F., Ignjatovic V., et al. Reduced bone density in children on long-term warfarin. Pediatr Res 57 (2005) 578-581
6. Batchelor T.T., Taylor L.P., Thaler H.T., et al. Steroid myopathy in cancer patients. Neurology 48 (1997) 1234-1238
7. Bikle D.D., Halloran B., Fong L., et al. Elevated 1,25-dihydroxyvitamin D levels in patients with chronic obstructive pulmonary disease treated with prednisone. J Clin Endocrinol Metab 76 (1993) 456-461
8. Blair M.M., Carson D.S., and Barrington R. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis. J Fam Pract 49 (2000) 839-848
9. Bonnick S.L., and Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 119 (2006) S25-S31
10. Braam L.A., Knapen M.H., Geusens P., et al. Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int 73 (2003) 21-26
11. Caraballo P.J., Heit J.A., Atkinson E.J., et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 159 (1999) 1750-1756
12. Cheruku R., Tapazoglou E., Ensley J., et al. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 68 (1991) 2621-2624
13. Chesnut III C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 109 (2000) 267-276
14. Chiu K.Y., Pun W.K., Luk K.D., et al. A prospective study on hip fractures in patients with previous cerebrovascular accidents. Injury 23 (1992) 297-299
15. Choucair A.K., Silver P., and Levin V.A. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 66 (1987) 357-358
16. Chung S., and Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 16 (1994) 382-385
17. Collins N., Maher J., Cole M., et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 78 (1991) 113-122
18. Constantini S., Kornowski R., Pomeranz S., et al. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta Neurochir (Wien) 109 (1991) 93-97
19. Cooper C., and Wickham C. Rheumatoid arthritis, corticosteroid therapy and fracture of the proximal femur. J Bone Miner Res 5 (1990) S109
20. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168 (1993) 1265-1270
21. Dahlman T.C., Sjoberg H.E., and Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 170 (1994) 1315-1320
22. Dent C.E., Richens A., Rowe D.J., et al. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 4 (1970) 69-72
23. Devogelaer J.P., Goemaere S., Boonen S., et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17 (2006) 8-19
24. Dykman T.R., Gluck O.S., Murphy W.A., et al. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 28 (1985) 361-368
25. Elliot K.J., Millward-Sadler S.J., Wright M.O., et al. Effects of methotrexate on human bone cell responses to mechanical stimulation. Rheumatology (Oxford) 43 (2004) 1226-1231
26. Ensrud K.E., Walczak T.S., Blackwell T., et al. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62 (2004) 2051-2057
27. Farhat G., Yamout B., Mikati M.A., et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58 (2002) 1348-1353
28. Feldkamp J., Becker A., Witte O.W., et al. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 108 (2000) 37-43
29. Food and Nutrition Board. Standing committee on the scientific evaluation of dietary reference intakes (1997) Washington (DC)
30. Friedman A.W. Important determinants of bone strength: beyond bone mineral density. J Clin Rheumatol 12 (2006) 70-77
31. Garfin S.R., Yuan H.A., and Reiley M.A. New technologies in spine: kyphoplasty and vertebroplasty for the treatment of painful osteoporotic compression fractures. Spine 26 (2001) 1511-1515
32. Gilsanz V., Carlson M.E., Roe T.F., et al. Osteoporosis after cranial irradiation for acute lymphoblastic leukemia. J Pediatr 117 (1990) 238-244
33. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 (2000) 1886-1893
34. Gough H., Goggin T., Bissessar A., et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 59 (1986) 569-577
35. Gouin-Thibault I., Pautas E., and Siguret V. Safety profile of different low-molecular-weight heparins used at therapeutic dose. Drug Saf 28 (2005) 333-349
36. Graves III L., and Lukert B.P. Glucocorticoid-induced osteoporosis. A clinician's perspective. Clin Rev in Bone and Min Metabol 2 (2004) 79-90
37. Grisso J.A., Kelsey J.L., Strom B.L., et al. Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med 324 (1991) 1326-1331
38. Guise T.A., and Mundy G.R. Cancer and bone. Endocr Rev 19 (1998) 18-54
39. Hahn T.J., Hendin B.A., Scharp C.R., et al. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287 (1972) 900-904
40. Handschin A.E., Trentz O.A., Hoerstrup S.P., et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 92 (2005) 177-183
41. Heller H.J., and Sakhaee K. Anticonvulsant-induced bone disease: a plea for monitoring and treatment. Arch Neurol 58 (2001) 1352-1353
42. Hildebrand J., Lecaille C., Perennes J., et al. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65 (2005) 212-215
43. Hirsh J. Heparin. N Engl J Med 324 (1991) 1565-1574
44. Holick M.F. Vitamin D and bone health. J Nutr 126 (1996) 1159S-1164S
45. Horber F.F., Scheidegger J.R., Grunig B.E., et al. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest 15 (1985) 302-307
46. Jacobs R.P. Drug-induced rheumatic diseases. Compr Ther 10 (1984) 65-72
47. Jamal S.A., Browner W.S., Bauer D.C., et al. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 128 (1998) 829-832
48. Karlsson M.K., Hasserius R., Gerdhem P., et al. Vertebroplasty and kyphoplasty: new treatment strategies for fractures in the osteoporotic spine. Acta Orthop 76 (2005) 620-627
49. Kelman A., and Lane N.E. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol 19 (2005) 1021-1037
50. Khanna A.J., Reinhardt M.K., Togawa D., et al. Functional outcomes of kyphoplasty for the treatment of osteoporotic and osteolytic vertebral compression fractures. Osteoporos Int 17 (2006) 817-826
51. Koch H.U., Kraft D., von Herrath D., et al. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 13 (1972) 829-834
52. Krishnamoorthy P., Freeman C., Bernstein M.L., et al. Osteopenia in children who have undergone posterior fossa or craniospinal irradiation for brain tumors. Arch Pediatr Adolesc Med 158 (2004) 491-496
53. LaRoche S.M., and Helmers S.L. The new antiepileptic drugs: scientific review. JAMA 291 (2004) 605-614
54. LeBlanc A.D., Evans H.J., Marsh C., et al. Precision of dual photon absorptiometry measurements. J Nucl Med 27 (1986) 1362-1365
55. Lieberman I.H., Dudeney S., Reinhardt M.K., et al. Initial outcome and efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. Spine 26 (2001) 1631-1638
56. Mazanec D.J., and Grisanti J.M. Drug-induced osteoporosis. Cleve Clin J Med 56 (1989) 297-303
57. Mazziotti G., Angeli A., Bilezikian J.P., et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab (2006)
58. Melton III L.J., Khosla S., Atkinson E.J., et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12 (1997) 1083-1091
59. Mithal N.P., Almond M.K., Evans K., et al. Reduced bone mineral density in long-term survivors of medulloblastoma. Br J Radiol 66 (1993) 814-816
60. Monreal M., Lafoz E., Olive A., et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71 (1994) 7-11
61. Monreal M., Olive A., Lafoz E., et al. Heparins, coumarin, and bone density. Lancet 338 (1991) 706
62. Montecucco C., Caporali R., Caprotti P., et al. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol 19 (1992) 1895-1900
63. Muir J.M., Andrew M., Hirsh J., et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88 (1996) 1314-1320
64. Muir J.M., Hirsh J., Weitz J.I., et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 89 (1997) 3236-3242
65. Mulley G., and Espley A.J. Hip fracture after hemiplegia. Postgrad Med J 55 (1979) 264-265
66. Naganathan V., Jones G., Nash P., et al. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 160 (2000) 2917-2922
67. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. 2003.
68. Nguyen T., and Zacharin M.R. Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia-two-year outcomes. J Pediatr Endocrinol Metab 19 (2006) 161-167
69. O'Brien C.A., Jia D., Plotkin L.I., et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145 (2004) 1835-1841
70. Onodera K., Takahashi A., Sakurada S., et al. Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 70 (2002) 1533-1542
71. Pack A.M. Antiepileptic drugs and bone disease. Clin Rev in Bone and Min Metabol 2 (2004) 159-165
72. Pack A.M., Gidal B., and Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med 71 Suppl 2 (2004) S42-S48
73. Patschan D., Loddenkemper K., and Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29 (2001) 498-505
74. Pettifor J.M., and Benson R. Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr 86 (1975) 459-462
75. Pettila V., Leinonen P., Markkola A., et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87 (2002) 182-186
76. Pluskiewicz W., and Nowakowska J. Bone status after long-term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneus and phalanges. Ultrasound Med Biol 23 (1997) 553-558
77. Poole K.E., Reeve J., and Warburton E.A. Falls, fractures, and osteoporosis after stroke: time to think about protection?. Stroke 33 (2002) 1432-1436
78. Poplingher A.R., and Pillar T. Hip fracture in stroke patients. epidemiology and rehabilitation. Acta Orthop Scand 56 (1985) 226-227
79. Quevedo J.F., Buckner J.C., Schmidt J.L., et al. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 69 (1994) 329-332
80. Rehman Q., Lang T.F., Arnaud C.D., et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14 (2003) 77-81
81. Reid I.R., and Ibbertson H.K. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 44 (1986) 287-290
82. Richens A., and Rowe D.J. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 4 (1970) 73-76
83. Rubin M.R., and Bilezikian J.P. Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87 (2002) 4033-4041
84. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 339 (1998) 292-299
85. Sato Y., Kondo I., Ishida S., et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57 (2001) 445-449
86. Sato Y., Maruoka H., Honda Y., et al. Development of osteopenia in the hemiplegic finger in patients with stroke. Eur Neurol 36 (1996) 278-283
87. Sawaya R., Cummins C.J., and Kornblith P.L. Brain tumors and plasmin inhibitors. Neurosurgery 15 (1984) 795-800
88. Sawaya R., Decourteen-Meyers G., and Copeland B. Massive preoperative pulmonary embolism and suprasellar brain tumor: case report and review of the literature. Neurosurgery 15 (1984) 566-571
89. Sawaya R., and Glas-Greenwalt P. Postoperative venous thromboembolism and brain tumors: part II. Hemostatic profile. J Neurooncol 14 (1992) 127-134
90. Sawaya R., Zuccarello M., Elkalliny M., et al. Postoperative venous thromboembolism and brain tumors: part I. Clinical profile. J Neurooncol 14 (1992) 119-125
91. Sheth R.D., Wesolowski C.A., Jacob J.C., et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127 (1995) 256-262
92. Simon R.R., and Shaughnessy S.G. Effects of anticoagulants on bone. Clin Rev in Bone and Miner Metabol 2 (2004) 151-158
93. Simon R.R., Beaudin S.M., Johnston M., et al. Long-term treatment with sodium warfarin results in decreased femoral bone strength and cancellous bone volume in rats. Thromb Res 105 (2002) 353-358
94. Sinaki M. Exercise and osteoporosis. Arch Phys Med Rehabil 70 (1989) 220-229
95. Souverein P.C., Webb D.J., Weil J.G., et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 66 (2006) 1318-1324
96. Stephen L.J., McLellan A.R., Harrison J.H., et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 8 (1999) 339-342
97. Takahashi A., Onodera K., Shinoda H., et al. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 82 (2000) 82-84
98. Takata S., and Yasui N. Disuse osteoporosis. J Med Invest 48 (2001) 147-156
99. Theodorou D.J., Theodorou S.J., Duncan T.D., et al. Percutaneous balloon kyphoplasty for the correction of spinal deformity in painful vertebral body compression fractures. Clin Imaging 26 (2002) 1-5
100. Tolman K.G., Jubiz W., Sannella J.J., et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 56 (1975) 45-50
101. Valmadrid C., Voorhees C., Litt B., et al. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 58 (2001) 1369-1374
102. van Staa T.P., Leufkens H.G., Abenhaim L., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39 (2000) 1383-1389
103. Vernillo A.T., Rifkin B.R., and Hauschka P.V. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 11 (1990) 309-312
104. Verrotti A., Greco R., Latini G., et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43 (2002) 1488-1492
105. Verrotti A., Greco R., Morgese G., et al. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47 (2000) 385-388
106. Walsh L.J., Wong C.A., Pringle M., et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ 313 (1996) 344-346
107. Wawrzynska L., Tomkowski W.Z., Przedlacki J., et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 33 (2003) 64-67
108. Weinstein R.S., Jilka R.L., Parfitt A.M., et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102 (1998) 274-282
109. Wheeler D.L., Vander Griend R.A., Wronski T.J., et al. The short- and long-term effects of methotrexate on the rat skeleton. Bone 16 (1995) 215-221
110. Whitlon D.S., Sadowski J.A., and Suttie J.W. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 17 (1978) 1371-1377
111. Winquist E.W., Bauman G.S., and Balogh J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol 24 (2001) 603-606